Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jul 12, 2020
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific surgical technique, called limited decompression, may help prevent problems in the spine after a common surgery known as posterior lumbar interbody fusion (PLIF). This trial focuses on patients who already have some narrowing of the spinal canal at nearby areas but are not currently experiencing any symptoms. The research aims to see if performing this preventive procedure can improve outcomes for patients who are undergoing surgery for degenerative spinal conditions.
To be eligible for the trial, participants should be between the ages of 65 and 74 and have a clear diagnosis of lumbar spinal stenosis, which is a condition where the space around the spinal cord narrows. They must have already tried conservative treatments, like physical therapy or medication, for at least eight weeks without improvement. However, those with certain spinal instability issues, infections, tumors, or a history of previous spine surgeries cannot participate. If you join the study, you will be closely monitored to assess the effects of the surgery, helping to contribute valuable information to the field of spinal health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clear diagnosis of lumbar spinal stenosis, and surgical level of L4-S1 (The levels to be operated on were decided by matching the clinical symptomatology with the radiological findings of the spinal levels that needed decompression);
- • Patients have asymptomatic pre-existing spinal canal stenosis (cerebrospinal fluid occlusion grade=1) at adjacent segment.
- • Failed at least eight weeks conservative treatment;
- Exclusion Criteria:
- • Unstable factors (slip, rotation, lateral bending, etc.) in adjacent segment L3/4;
- • Preoperative sagittal and coronal imbalance of the spine;
- • Lumbar infection and/or tumor diseases;
- • A previous history of lumbar fusion surgery.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
Patients applied
Trial Officials
Wei Shi Li, Dr.
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials